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140 Poster Session IIby day 4 as efficiently as wt B6 T cells, with a similar reduction in
pEC viability, from 93 6 6.7 to 43 6 6.4 in the presence of gld T
cells and 446 8.6 in the presence of wt B6 T cells (p . 0.5). How-
ever, upregulation of Fas on pEC co-cultured with gld T cells was
delayed and seen only by day 4 rather than day 2. The capacity of
gld T cells to modulate the epithelial environment appears intact,
since they induced the upregulation of H2Kb by 10-fold and IAb
by 3-fold on the pEC, similar to the effect induced by wt B6 T cells.
We also found higher interferon gamma (IFNg) in the supernatants
of co-cultures with gld T cells (141.26 17.8), as compared to wt B6
T cells (100.3 6 20.1, p\ 0.004). However, in contrast to the ex-
pression of H2Kb and IAb which were up-regulated 5.5-fold and
2.8-fold by IFNg added to pEC cultures, Fas expression was not al-
tered by this cytokine even after 7 days and at high doses (50 and 500
ng/ml). In summary, T cells increased the expression of Fas on
miHA-mismatched pEC. This event was of no evident conse-
quence, since FasL expression on ‘‘donor’’ T cells was not required
to kill ‘‘host’’ pEC in the 4-day period studied. FasL-deficient T
cells also modulated the expression of epithelial MHC molecules
and might be associated with the high levels of IFNg, a key cytokine
during GVHD, detected in supernatants of co-cultures. However,
IFNg did not regulate Fas on pEC, indicating that other cyto-
kines/mechanisms are responsible for this effect. Altogether, our re-
sults suggest that the Fas-FasL pathway may have a minor role in
the early pathogenesis of cutaneous GVHD.384
DACLIZUMAB AND INFLIXIMAB FOR TREATMENT OF STEROID RESIS-
TANT ACUTE GRAFT VERSUS HOST DISEASE (aGVHD) IN PEDIATRICS
Snyder, R.L., Daum, C., Klinger, E., Neudorf, S., Simpson, L. Children’s
Hospital of Orange County, Orange, CA.
Patients with steroid resistant aGVHD have a poor prognosis.
Daclizumab (anti-IL2 receptor alpha chain), and infliximab (anti-
TNF) have shown activity in early clinical trials in adults. We are
reporting our experience using daclizumab and infliximab in 3 pedi-
atric patients. All received daclizumab (1 mg/kg/dose IV on days 1,
4, 8, 15 and 22 and infliximab (10 mg/kg/dose IV on days 1, 8, 15
and 22). Steroid tapering was at the discretion of the attending phy-
sician based on clinical condition and response to treatment.
UPN 377 was a 19 month old girl with Hemophagocytic Lym-
phohistiocytosis who received a related bone marrow graft matched
for 8/8 alleles. She received a preparative therapy consisting of bu-
sulfan, VP16 and cytoxan and methotrexate (mtx) and cyclosporine
(csa) for GVHD prophylaxis. She developed stage 3 grade 2
aGVHD of the skin on d1 32 post transplant. After 19 days of ste-
roids (2 mg/kg/day), daclizumab and infliximab were started.
GVHD improved by d 1 36. The patient developed extensive
chronicGVHDand is presently 522 days post transplantwith aLan-
sky score of 100%.
UPN 394 was an 8 yr old male with ALL in CR2 who received
a related bone marrow graft matched for 5/8 alleles. He received
TBI, VP16 and cytoxan and mtx and csa for GVHD prophylaxis.
He developed stage 3 grade 2 aGVHD of the skin on d 1 24 post
transplant. After 2 days of steroids (4 mg/kg/day), he was treated
with daclizumab and infliximab. GVHD improved by d 1 31.
The patient has extensive chronic GVHD. He is 210 days post
transplant and has a Lansky score of 100%.
UPN 395 was a 13 month old male with ALL in CR1 who re-
ceived an unrelated bone marrow graft matched for 8/8 alleles.
He received TBI, VP16 and cytoxan and csa and mtx for GVHD
prophylaxis. He developed stage 3 grade 2 aGVHD of the skin on
d 1 19 post transplant. After 11 days of steroids (2 mg/kg/day),
he was treated with daclizumab and infliximab. GVHD improved
by d 1 33. The patient relapsed at d 1 189 post transplant and
has no signs of chronic GVHD.
In all patients, there were no instances of opportunistic viral or
fungal infections. This small series suggests that the combination
of daclizumab and infliximab is well tolerated and an effective ther-
apy for steroid resistant GVHD in pediatrics. Therefore, we have
revised our algorithm for the management of aGVHD (to be dis-
played at the meeting).385
MONOCYTE BLOOD COUNT AND ACUTE GVHD: FLOW CYTOMETRY
ANALYSIS RECOMMENDED IN PROSPECTIVE STUDIES
Chunduri, S.1, Arpinati, M.2, Singh, V.3, Shuaipaj, T.1, Mehta, J.3,
Rondelli, D.1. 1 University of Illinois at Chicago, Chicago, IL; 2 University
of Bologna, Bologna, Italy; 3 Northwestern University, Chicago, IL.
Patients with a high absolute number of peripheral bloodCD141
monocytes prior to starting the conditioning regimen have been
shown to have a greater risk of developing acute graft-versus-host
disease (aGVHD) (Arpinati et al. BBMT 2007) after allogeneic he-
matopoietic stem cell transplantation (HSCT). In this study, we ini-
tially pooled the data of 154 consecutive patients with hematologic
malignancies who received an allogeneic peripheral blood stem cell
transplant at three different institutions, utilizing myeloablative (n
5 36) or reduced intensity conditioning (n5 118) regimens not in-
cluding ATG. The blood absolute monocyte count (AMC) was as-
sessed before starting the conditioning regimen and it was
calculated by dividing the absolute white cell count by the percent-
age of monocytes obtained with an automated CBC. The median
value of AMC in the study was 0.5  109/L (range:0.0–11.8). Of
154 patients, 73 had\ 0.5 and 81 had $0.5 AMC  109/L prior
to starting the conditioning regimen. All the patients received an
8/8 HLA antigen matched graft from related (n5 114) or unrelated
(n 5 40) donors. In the group of patients with lower AMC the me-
dian age was 51 (range:19–71) and donors were unrelated in 27%
and sexmismatched in 41%of the cases, whereas in the group of pa-
tients with higher AMC median age was 50 (range:18–63) and do-
nors were unrelated in 25% and sex mismatched in 36% of the
cases. The rate of acute GVHD grade II-IV in patients with low
or high AMC was 44% and 38%, respectively (p5ns). To test
whether the AMC obtained by means of automated CBC was com-
parable to the absolute count of CD141 monocytes detected by
flow cytometry, blood samples from 43 patients were analyzed uti-
lizing both techniques. In this series of patients, mean values of
AMC and CD141 blood cells were 11.9 6 11.9 and 7.3 6 6.9 
109/L and median values were 9.6 (range 95% CI:8.2–15.6) and
6.0 (range 95% CI:5.2–9.5)  109/L, respectively, (p 5 0.0004).
In this study, the analysis of monocyte absolute count by automated
CBC did not confirm the correlation between high levels of blood
CD141 cells analyzed by flow cytometry and development of
aGVHD. Since we demonstrate here that the absolute number of
monocytes obtained by cytofluorimetric expression of CD14 is sig-
nificantly different as compared to that obtained by automated
CBC, future prospective studies addressing the prognostic role of
monocyte blood count in allogeneic HSCT should be performed
utilizing a flow cytometry-based method.386
SIROLIMUS IN COMBINATION WITH CYCLOSPORINE OR TACROLIMUS
PLUS METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE (GVHD)
PROPHYLAXIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION
FROM UNRELATED DONORS
Furlong, T., Kiem, H.-P., Appelbaum, F.R., Carpenter, P.A., Deeg, J.,
Doney, K., Flowers, M.E.D., Mielcarek, M., Nash, R.A., Storb, R.,
Martin, P.J. Fred Hutchinson Cancer Research Center, Seattle, WA.
Sirolimus (SIR) is reported to be effective in preventing GVHD
when combined with tacrolimus (TAC) and methotrexate (MTX)
after related and unrelated allogeneic hematopoietic cell transplan-
tation (HCT). In two consecutive clinical trials, we evaluated the ef-
ficacy of SIR plus cyclosporine (CSPGroup) or TAC (TACGroup)
and MTX after unrelated HCT. SIR was administered as a 12 mg
PO loading dose on day -1 (CSP Group) or -3 (TAC Group) fol-
lowed by 4 mg PO QD. SIR levels were targeted at 4–14 ng/mL
in the CSP Group and 3–12 ng/mL in the TAC Group. The dose
of CSP was 1.5 mg/kg Q12h IV starting on day -1, and the dose
of TACwas 0.02mg/kg/day IV starting on day -3. CSPwas targeted
at 150–450 ng/mL and TAC at 5–10 ng/mL. All patients received
MTX 5 mg/m2 IV on days 1, 3, 6 and 11. Nine patients were
Poster Session II 141enrolled in the SIR/CSP study and 17 in the SIR/TAC study. All
patients had high-risk hematologic malignancies. Twenty four
patients had HLA-matched donors and 22 received growth fac-
tor-mobilized peripheral blood cells. The preparative regimens
were total body irradiation/cyclophosphamide (CY) (17) or busul-
fan/CY (9). Grade II-IV acute GVHD was observed in 20 (91%)
of 22 patients who could be evaluated, 7 of 7 in the CSP Group
and 13 of 15 in the TAC Group, and all required glucocorticoid
therapy. Four patients could not be evaluated due to early death
(1) or glucocorticoid treatment for pulmonary complications (3).
The median onset of GVHD was day 6 and 7 in the CSP and
TAC Groups, respectively. GVHD was confirmed by biopsy in
16 patients. Mean SIR levels through day 30 were 11.7 and
8.8 ng/mL in the CSP and TAC Groups, respectively, with only
2% and 11% of levels below the target range. At the onset of
GVHD, 5 patients (26%) had SIR levels below the target range.
The mean CSP and TAC levels through day 30 were 324 ng/mL
and 9.6 ng/mL, respectively, with 2 patients in the TACGroup hav-
ing levels below the target range at the onset of GVHD. Twelve of
26 patients (46%) discontinued administration of SIR early due to
cytopenia (5), hemolytic-uremic syndrome or renal failure (4), ab-
normal liver function tests (1), hyperlipidemia (1) or elevated siroli-
mus level (1). Three patients in the TAC Group required
hemodialysis. Nineteen of 20 patients developed GVHD before
SIR was discontinued. Sixteen patients (62%) were alive at one
year after HCT. Accrual in both studies was terminated when it be-
came apparent that there was no detectable improvement inGVHD
incidence.387
EFFECT OF ACUTE AND CHRONIC GVHD ON OVERALL SURVIVAL IN 122
UNRELATED TRANSPLANTS FOR MALIGNANT DISEASES PERFORMED
OVER TEN YEARS IN A SINGLE CENTER IN BRAZIL
Funke, V.A.M., Nunes, E.C., Medeiros, L., Setubal, D.C., Ruiz, J.,
Oliveira, M.M., Bittencourt, M.A., Bonfim, C., Neto, J.Z.,
Medeiros, C.R., Pasquini, R. Hospital de Clınicas - Federal University
of Parana, Curitiba, Parana, Brazil.
Acute and chronic graft-versus-host disease are well known
causes of transplant related mortality among unrelated transplants.
Objective: evaluate the impact of acute and chronicGVHDat the
overall survival among 122 unrelated transplants performed from
07/95 to 06/05 at the BMT center of HC-UFPR in Curitiba, Brazil.
PATIENTS CHARACTHERISTICS: male: 78; female: 44; me-
dian age 17.5 years (range: 1–55). Cell source was bone marrow in
91 patients, cord blood in 29 patients and pheripheral blood in 2 pa-
tients. Conditioning regimen was nomyeloablative in 8 patients and
conventional in 114 patients. 24 patients received ATG or ALG as
part of their conditioning regimen. 39 patients had advanced disease
at the time of transplant (CML advanced phase, AML or ALL in re-
lapse or refractory). Results: Acute graft versus host disease grade
II-IV was observed in 49 patients (40%). Extensive chronic
GVHD was observed in 26 patients (21%). Acute GVHD was the
primary cause of death in 4% and chronic GVHD in 9%, infection
in 22% and relapse in 19% of the patients. Acute or chronic GVHD
was not statistically different amog alive and dead patients. Among
91 patients who received marrow or pb, acute graft-versus-host dis-
ease grade II-IV was seen in 41 patients (45%). 54 patients survived
more than 100 days and were then evaluable for chronic graft-ver-
sus-host-disease. 24 (44%) of them developed extensive chronic
GVHD. A-GVHD and C-GVHD were the primary cause of death
in 5 (8%) and 11 (18%) patients respectively. Infection (37%) and
relapse (27%)were themost frequent causes of death. Among 83 pa-
tients who received unrelated cord blood, grade II-IV acute GVHD
was seen in 29% of the patients. Chronic GVHD was observed in
16% of the 44 patients who survived more than 100 days. Acute
GVHDwere considered as primary cause of death in 7% of the pa-
tients. Infection (20%) and relapse (11%) were the main causes of
death. There was significantly more patients alive with c-GVHD.
Conclusion: The presence of chronic graft-versus-host-disease
had a protective effect at the survival of this group of patients, prob-
ably due to graft-versus-malignancy effect.388
PRIMARY TREATMENT AND PROGNOSIS OF ACUTE GRAFT-VERSUS-
HOST DISEASE (GVHD): A SINGLE-CENTER ANALYSIS OF 458 PATIENTS
Fukuda, T., Yokoyama, H., Takahashi, T., Iisaka, Y., Ohara-Waki, F.,
Kim, S.-W., Mori, S.-I., Tanosaki, R., Tobinai, K., Takaue, Y. National
Cancer Center Hospital, Tokyo, Japan.
Purpose and Methods: To clarify the optimal primary treat-
ment for acute GVHD (aGVHD) and to identify prognostic factors
that can predict outcome after aGVHD, we retrospectively re-
viewed the data of 458 patients (median age, 47 years: range, 1–
68) with hematological malignancies who underwent allogeneic
HCT between 2000 and 2006. Patients were conditioned with a re-
duced-intensity (n 5 249) or myeloablative regimen (n 5 209). Pa-
tients received BM (n5 168), G-CSF-mobilized PBSC (n5 256) or
CB (n5 34) from either an HLA-matched relative (n5 214), a mis-
matched relative (n 5 56) or an unrelated volunteer (n 5 188).
GVHD prophylaxis consisted of cyclosporine (n 5 397) or tacroli-
mus (n5 61), with or without methotrexate. The median follow-up
of surviving patients was 1379 days. Results: Grade I-IV aGVHD
occurred in 242 patients, and the timing was before disease progres-
sion or relapse in 236 patients (grade I, n 5 33; grade II, n 5 126;
grade III, n 5 57; grade IV, n 5 20). The incidence of nonrelapse
mortality (NRM) in these 236 patients with aGVHD was 32%
(grade I, 3%; grade II, 26%; grade III/IV, 53%). While 65 patients
(28%) were followed without systemic corticosteroids (grade I, n5
28; grade II, n5 37), the remaining 171 patients (72%) received sys-
temic corticosteroids as a primary treatment for aGVHD (mPSL
equivalents $2 mg/kg/day, n 5 35; 1 mg/kg/day, n 5 103; 0.2–
0.5 mg/kg/day, n 5 33). Subsequently, 62 patients were treated
with an increased dose of corticosteroids, and 25 required additional
treatment. The 2-year NRM in 70 patients with grade II GVHD
with skin involvement alone and 19 patients with upper-GI
GVHD with or without skin involvement were 20% and 19%, re-
spectively, although 36% and 79% of the patients were treated
with#0.5 mg/kg/day of mPSL. While the 2-year NRM in 112 pa-
tients who had liver or lower-GI involvement was 50%, that in 124
patients who did not was 15% (p\0.0001). In a multivariate anal-
ysis, liver or lower-GI involvement, GVHDonset within 14 days af-
ter HCT, older patient age, cyclosporine prophylaxis, and
transplant from a donor other than an HLA-matched relative
were associated with an increased risk for NRM after the develop-
ment of aGVHD. Conclusions: The initial dose of systemic corti-
costeroids can be reduced safely when GVHD manifestation
involvesmainly the skin and upperGI. Although prospective studies
are needed to confirm these findings, our study suggests that
GVHD treatment can be tailored depending on ethnicity and trans-
plantation procedures.389
EOSINOPHILIC PULMONARY SYNDROME AS A MANIFESTATION OF PUL-
MONARY GRAFT-VERSUS-HOST-DISEASE FOLLOWING HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN THREE PATIENTS
Akhtari, M.1, Lanston, A.1, Waller, E.1, Gal, A.2. 1 Winship Cancer In-
stitute, Emory University School of Medicine, Atlanta, GA; 2 Emory Uni-
versity School of Medicine, Atlanta, GA.
Eosinophilic pulmonary syndrome has been an uncommon prob-
lem in stem cell transplant recipients that can mimic an infectious
process. We report the occurrence of three cases of eosinophilic
pulmonary syndrome as a manifestation of pulmonary graft-ver-
sus-host-disease (GVHD) in the setting of allogeneic hematopoietic
stem cell transplantation (HSCT), after day 100 post-transplant, for
hematological disorders. All three patients had skinGVHDcompli-
cating their post-transplant course. All three patients had peripheral
blood eosinophilia with their lung biopsies showing pronounced in-
filtrates of eosinophils involving bronchioles. Following the admin-
istration of high-dose systemic steroid therapy, all patients
responded rapidly with improvement of their pulmonary symptoms
and the resolution of peripheral blood eosinophilia. Clinicians
should be aware that eosinophilic pulmonary syndrome can occur
following HSCT and it can be associated with GVHD.
